Related Experiment Video
Updated: Apr 27, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Implanting cardiac rhythm devices during uninterrupted warfarin therapy: a prospective, single center experience
Martino Crosato1, Vittorio Calzolari, Enrico Franceschini Grisolia
1aDivision of Cardiology, Ospedale Civile di Treviso 'Ca' Foncello', Treviso bDivision of Cardiology, Ospedale di Cesena 'Bufalini', Cesena, Italy.
Insights
Cardiac rhythm device implantation is safe without interrupting warfarin therapy. This study found no increased bleeding risk in patients on uninterrupted warfarin compared to those who stopped the medication before their procedure.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Device Implantation
Background:
- Oral anticoagulant therapy, particularly warfarin, is crucial for patients with high thromboembolic risk.
- Traditional practice often involves interrupting warfarin before cardiac rhythm device implantation, increasing stroke risk.
- Assessing the safety of uninterrupted warfarin during these procedures is vital for patient management.
Purpose of the Study:
- To evaluate the safety of implanting cardiac rhythm devices (pacemakers, defibrillators) while patients remain on uninterrupted warfarin.
- To compare bleeding complication rates between patients undergoing device implantation on uninterrupted warfarin versus those who stopped warfarin.
Main Methods:
- A comparative study involving 191 patients undergoing cardiac rhythm device implantation.
- The 'on warfarin group' (n=102) had procedures during uninterrupted warfarin therapy.
- The 'off warfarin group' (n=89) underwent procedures after warfarin withdrawal; this group included lower-risk patients for comparison.
Main Results:
- No significant difference in hematoma incidence (5% vs. 3%, P=not significant) between the 'on warfarin' and 'off warfarin' groups.
- All hematomas observed were minor and resolved spontaneously.
- There were no instances of death, hemothorax, tamponade, or significant bleeding complications in either group; no thromboembolic events occurred within 2 months.
Conclusions:
- Cardiac rhythm device implantation can be safely performed without interrupting warfarin therapy in high-risk patients.
- Uninterrupted warfarin does not appear to increase the risk of significant bleeding complications compared to warfarin interruption.
- This approach may help mitigate thromboembolic risks associated with discontinuing anticoagulation.
Aim:
The aim of the present study was to assess the safety of cardiac rhythm device implantation during uninterrupted oral anticoagulant therapy.
Methods:
Patients at high thromboembolic risk (venous thromboembolism <3 months, nonvalvular atrial fibrillation with CHADS2 score >2, valvular atrial fibrillation, prosthetic heart valves) underwent procedures during uninterrupted warfarin (on warfarin group) and were compared to low-risk patients who underwent procedures after warfarin withdrawal (off warfarin group). Primary endpoint was a composite of hematoma requiring warfarin interruption, reoperation, or blood transfusion; death; hemothorax; and tamponade. Secondary endpoints were nonsignificant hematoma and clinical arterial thromboembolism assessed at discharge and at a 2 month follow-up.
Results:
One hundred and ninety-one patients were enrolled, 102 in the 'on warfarin group' and 89 in the 'off warfarin group'. The majority of procedures were first implants (73% in the 'on warfarin group' vs. 87% in the 'off warfarin group', P= 0.01). Pacemakers, implantable cardioverter defibrillators, and biventricular devices were included. International normalized ratio at implant was 2 ± 0.28 (range 1.6-3.2) in the 'on warfarin group' and 1.3 ± 0.19 (range 1-1.6) in the 'off warfarin group' (P= 0.0001). Incidence of hemathoma was five of 102 in the 'on warfarin group' vs. three of 89 in the 'off warfarin group' (5 vs. 3%, P = not significant) and all hemathomas resolved spontaneously. There were no significant hemathomas in either group. There was no death, hemothorax, or tamponade. There were no thromboembolic events at 2 months.
Conclusion:
Cardiac rhythm device implantation during uninterrupted warfarin was not associated with increased bleeding compared with warfarin interruption.
More Related Videos
Related Concept Videos
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Dysrhythmias VI: Management of Dysrhythmias
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Cardiac Catheterization IV: Nursing Management
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Cardiomyopathy V: Interprofessional Care

